Apogee Therapeutics (APGE) Non-Current Assets (2023 - 2026)
Apogee Therapeutics (APGE) posted quarterly Non-Current Assets of $219.9 million for Q1 2026, up 14.13% year-over-year from $192.6 million in Q1 2025, and up 12.3% quarter-over-quarter from $195.8 million in Q4 2025.
Apogee Therapeutics (APGE) Non-Current Assets (2023 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Non-Current Assets for 4 consecutive years, with $219.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 14.13% year-over-year to $219.9 million; the TTM figure through Mar 2026 stood at $643.3 million (down 17.25% YoY), while the FY2025 annual figure was $195.8 million, down 12.69% from the prior year.
- Non-Current Assets improved to $219.9 million in Q1 2026 per APGE's latest filing, from $195.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $241.8 million in Q3 2024 and bottomed at $3.0 million in Q4 2023.
- Historically, Non-Current Assets has averaged $142.7 million across 4 years, with a median of $167.1 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Assets surged 7387.08% — and 2025, when it plunged 64.41%.
- Apogee Therapeutics' Non-Current Assets stood at $3.0 million in 2023, then soared by 7387.08% to $224.2 million in 2024, then declined by 12.69% to $195.8 million in 2025, then increased by 12.3% to $219.9 million in 2026.
- Business Quant data shows APGE's Non-Current Assets at $219.9 million in Q1 2026, $195.8 million in Q4 2025, and $86.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | 344.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 344.08 Mn |
| Mar 31, 2026 | 219.86 Mn |
| Dec 31, 2025 | 195.78 Mn |
| Sep 30, 2025 | 86.06 Mn |
| Jun 30, 2025 | 141.65 Mn |
| Mar 31, 2025 | 192.63 Mn |
| Dec 31, 2024 | 224.24 Mn |
| Sep 30, 2024 | 241.80 Mn |
| Jun 30, 2024 | 118.80 Mn |
| Mar 31, 2024 | 3.05 Mn |
| Dec 31, 2023 | 3.00 Mn |